Clinical trials: Cytochrome P-450 CYP2D6
Healthy
Absolute Bioavailability of Lu AE58054 in Healthy Subjects
To determine the absolute bioavailability of the Lu AE58054 tablet formulation at steady state
- Trial name
- NCT02019394
- Testing
- Lu AE58054
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Liver Cirrhosis
Predicting Response and Exposure Changes in Cirrhosis for Effectiveness
The goal of this clinical trial is to learn how liver cirrhosis affects the way the body processes drugs in adults with different stages of liver cirrhosis.
- Trial name
- PRECISE (NCT07750587)
- Testing
- Five-Drug CYP Probe Cocktail
- Volunteers
- 45 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Substance Use Disorder
OPAL: "Opiates and PhArmacoLogy"
The aim of this study is to determine the current prevalence of co-addictions, including problem/pathological gambling, in patients receiving Opiate Substitution Treatment (OST), and to then compare patients receiving OST with or…
- Trial name
- OPAL (NCT01847729)
- Where
- 7 sites in France
- Volunteers
- 263 people
- Sponsor
- Nantes University Hospital
Healthy
Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol
A Clinical Study to Evaluate the Effect of Cytochrome P450 2D6 polymorphism on Pharmacokinetics/Pharmacodynamics After Multiple Administration of Carvedilol
- Trial name
- NCT02286934
- Testing
- Carvedilol, Isoproterenol Sensitivity Test
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol
The purpose of this study is to determine the effect of JNJ-55308942: 1) high dose at steady state on the single dose pharmacokinetics of a cocktail containing selective probes of cytochrome P450 (CYP) enzymes (CYP3A, CYP2D6 and…
- Trial name
- NCT03547024
- Testing
- JNJ-55308942 High Dose, JNJ-55308942 Low Dose, Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Cytochrome P450 2D6 Ultra-rapid Metabolism
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk
The purpose of this study is to determine if non-invasive salivary genetic screening of breastfeeding mothers taking codeine will allow for the successful identification of mother-infant pairs susceptible to adverse events and to…
- Trial name
- NCT01050400
- Testing
- Cytochrome P450 2D6 (CYP2D6) genetic screening.
- Where
- Canada
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Liver Cirrhosis
A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
This study is open to healthy adults and adults with liver cirrhosis. The purpose of this study is to compare how different medicines are handled by the body in people with and without liver cirrhosis.
- Trial name
- NCT05741385
- Testing
- Caffeine, Warfarin sodium, Omeprazole
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Boehringer Ingelheim
Cytochrome P450 Phenotype and Genotype Metrics
Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes
The Cytochrome P450 enzymes are responsible for the metabolism of a wide range of drugs and other xenobiotics. Genetic variants of the encoding P450 genes have shown to influence the rate of metabolism of many clinically used…
- Trial name
- NCT00981929
- Testing
- Tramadol, Omeprazole, losartan, caffeine, Tramadol, omeprazole, losartan, caffeine
- Where
- Denmark
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
Metabolism, Alzheimer's Disease
Drug Interaction Study Between AZD3480 and Cytochrome P450
The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.
- Trial name
- Cocktail (NCT00692510)
- Testing
- AZD3480, Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Drug Resistance, Psychotropic Drugs
Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs
Psychotropic drugs are frequently used in children and adolescents in France with a prescription rate of 2.5%. Antipsychotics (PA) and antidepressants (AD), each concern 0.3% of the pediatric population (Kovess et al., 2015).
- Trial name
- M4P (NCT03114098)
- Testing
- gene abnormalities
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Fondation Lenval
Malaria
Single Low-dose Primaquine Efficacy and Safety.
Background: The World Health Organization has recommended addition of a 0.25 mg/kg single-dose primaquine (PQ) to standard artemisinin-based combination therapy (ACT) for elimination of malaria in low transmission-settings and…
- Trial name
- ESSLDPQP4502D6 (NCT03352843)
- Testing
- Primaquine
- Where
- Tanzania
- Volunteers
- 157 people
- Sponsor
- Tropical Pesticides Research Institute, Tanzania
Healthy
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.
- Trial name
- DDI (NCT01784536)
- Testing
- Single-Dose IV Oritavancin Diphosphate
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Melinta Therapeutics, Inc.
Depression, Depressive Disorder
Cytochrome P450-2D6 Screening Among Elderly Using Antidepressants (CYSCE)
Depression is common among elderly with an estimated prevalence of 5%. Due to ageing the national burden will double in the coming decade.
- Conditions
- Depression, Depressive Disorder, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Intermediate Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Trial name
- CYSCE (NCT01778907)
- Testing
- Genotype information accompanied by a drug dosing advice
- Where
- 11 sites in Netherlands
- Volunteers
- 202 people
- Sponsor
- University of Groningen
Schizophrenia
Pharmacokinetic Study of MIN-101 in Healthy Subjects
The aim of the study is to assess how MIN-101 is taken up by the body when given in different amounts and in different formulations.
- Trial name
- NCT02232529
- Testing
- MIN-101
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Minerva Neurosciences
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Healthy
Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes
CYP2D6 metabolizes ~25% of all marketed drugs. There is an important variability in the activity of this enzyme among individuals.
- Trial name
- ENDOCYP2D6 (NCT04188028)
- Testing
- Dextromethorphan 5 MG, Paroxetine 10Mg Tablet, Paroxetine 20Mg Tablet
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jules Desmeules
Drug Intolerance, Cytochrome P450 CYP2D6 Enzyme Deficiency
Evaluation of Pupillometry for cyp2d6 Phenotyping in Children Treated With Tramadol
Pupillometry will be performed before administration of tramadol, at T0 and then 1 to twice per hour in children having received tramadol as a pain killer as part of his/her routine care.
- Conditions
- Drug Intolerance, Cytochrome P450 CYP2D6 Enzyme Deficiency, Drug Effect
- Trial name
- PUPICYP (NCT03052218)
- Testing
- Pupillometry
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Geneva
Healthy
Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects
The purpose of this study is to determine if the relative difference in Pharmacokinetics (PK) between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single…
- Trial name
- NCT00727064
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR), Venlafaxine Extended Release (VEN ER)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Drug Metabolism Phenotype
Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics
Cytochrome P450 2D6 (CYP2D6) is an important enzyme in the body for breaking down many medications that are commonly used in children of various ages.
- Trial name
- NCT01118858
- Where
- 2 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City